Loading organizations...
Base4 Capital is an investment firm funding companies at the intersection of biology and information science. It backs ventures applying data science, computational methods, and engineering to biological challenges. The firm transforms biological processes into quantifiable systems, driving innovation in biotechnology, therapeutics, and diagnostics through actionable data insights.
Amol Kumar Jain, the firm's Managing Partner, brings a financial background including analyst experience at Duquesne Family Office LLC and Forbes' 30 Under 30 recognition. Base4 Capital was founded on the insight that merging biological discovery with advanced computational techniques offers profound opportunity for innovation and value creation.
The firm backs innovative companies across life science sectors, leveraging biological information via data-driven methodologies. Base4 Capital envisions a future where biological understanding is driven by information science, leading to novel treatments and sustainable solutions. Its long-term goal is cultivating pioneering enterprises redefining the biological industry.
Base4 Capital has 2 tracked investments across 2 companies. The latest tracked deal is $45.0M Series A in Centivax in July 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2025 | Centivax | $45.0M Series A | Future Ventures | Craft Ventures, Feenix Ventures, Lockheed Martin Ventures, MAC Venture Capital, NFX, Seraphim Space, Daniel Ammann, Elia Montanari, Keith Masback, Ryan Johnson, Amplify Partners, Bold Capital Partners, Kendall Capital Partners |
| Oct 1, 2023 | Mana.bio | $20.0M Seed | Andreessen Horowitz, Base4 Capital, LionBird, Technion | BoxOne Ventures, Aniq Kassam, NFX, Pioneer Fund |
